US2014377254A1PendingUtilityA1

Subtypes of humanized antibody against interleukin-6 receptor

63
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Mar 24, 2004Filed: Apr 14, 2014Published: Dec 25, 2014
Est. expiryMar 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Katsuhiro KanoIsamu Terashima
A61P 37/02A61P 37/06A61P 31/04A61P 35/00A61P 31/18A61P 29/00C07K 16/2866C07K 2317/24A61P 1/04C07K 2317/40A61P 17/06C07K 2317/52C07K 2317/76A61K 39/3955A61P 19/02A61P 13/12C07K 2317/92C07K 2317/14A61P 1/18
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH 2 (447), and an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH 2 (447), and a pharmaceutical composition comprising them.

Claims

exact text as granted — not AI-modified
1 . An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH 2  (447). 
     
     
         2 . An antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH 2  (447). 
     
     
         3 . The antibody subtype according to  claim 1  wherein the heavy chain of the native humanized PM-1 antibody corresponding to the subtype according to  claim 1  has an amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         4 . The antibody subtype according to  claim 3  wherein glutamine (Gln) at the heavy chain N-terminal is pyroglutamic acid (pGlu). 
     
     
         5 . The antibody subtype according to  claim 1  wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence set forth in SEQ ID NO: 2. 
     
     
         6 . A pharmaceutical composition comprising either the subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH 2  (447) or the subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH 2  (447), or both of the subtypes (1) and (2).

Join the waitlist — get patent alerts

Track US2014377254A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.